4D Advisors LLC Buys Shares of 200,000 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

4D Advisors LLC bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 200,000 shares of the medical device company’s stock, valued at approximately $7,204,000. Tandem Diabetes Care accounts for 5.0% of 4D Advisors LLC’s holdings, making the stock its 5th biggest holding. 4D Advisors LLC owned approximately 0.30% of Tandem Diabetes Care at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AlphaQuest LLC grew its position in shares of Tandem Diabetes Care by 138.7% during the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 541 shares during the period. Jones Financial Companies Lllp grew its holdings in Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock valued at $41,000 after purchasing an additional 748 shares during the period. Assetmark Inc. increased its position in Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock worth $44,000 after buying an additional 535 shares in the last quarter. McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the third quarter worth about $52,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after buying an additional 1,101 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TNDM. Canaccord Genuity Group raised their target price on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a “buy” rating in a research note on Thursday. Stifel Nicolaus dropped their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating for the company in a report on Thursday. Mizuho initiated coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a “neutral” rating and a $20.00 price target for the company. Piper Sandler lowered their price objective on Tandem Diabetes Care from $36.00 to $30.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $39.81.

Tandem Diabetes Care Trading Up 18.6 %

TNDM opened at $19.98 on Friday. The firm has a market cap of $1.33 billion, a P/E ratio of -10.35 and a beta of 1.52. The stock has a 50-day moving average of $19.04 and a 200 day moving average of $28.75. Tandem Diabetes Care, Inc. has a 12 month low of $15.75 and a 12 month high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The firm had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same quarter last year, the business posted ($0.65) EPS. Tandem Diabetes Care’s revenue was up 22.3% compared to the same quarter last year. As a group, research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is owned by company insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.